SCHEMBL470221

SCHEMBL470221

Cc1cc(Cl)c(N)cc1N1CCNCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 7/20 0.47
HTR3A P46098 3/20 0.46
HTR3E A5X5Y0 2/20 0.46
HTR3B O95264 2/20 0.46
HTR3D Q70Z44 2/20 0.46
HTR3C Q8WXA8 2/20 0.46
DRD2 P14416 2/20 0.44
DRD3 P35462 2/20 0.44
CHRNB2 P17787 1/20 0.43
CHRNA4 P43681 1/20 0.43
HTR7 P34969 2/20 0.41
HTR1A P08908 2/20 0.41
DRD4 P21917 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CHRM2 P08172 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL470181 0.87 ADRB1 (0.47) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL17884970 0.86 ADRB1 (0.53) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL30609616 0.86 ADRB1 (0.53) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL459418 0.84 ADRB1 (0.52) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL30609651 0.80 ALDH1A1 (0.50) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL17884850 0.80 ALDH1A1 (0.50) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL12457290 0.78 ADRB1 (0.45) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL2872887 0.78 HTR3A (0.57) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL7544806 0.77 ALDH1A1 (0.61) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL4930499 0.77 HSP90AA1 (0.51) ADRB1HTR3AHTR3EHTR3BHTR3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012033736-A1 NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-15 WO disclosed